Literature DB >> 19444675

HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Geetanjali Chander1, Seth Himelhoch, John A Fleishman, James Hellinger, Paul Gaist, Richard D Moore, Kelly A Gebo.   

Abstract

Mental illness (MI) and illicit drug use (DU) frequently co-occur. We sought to determine the individual and combined effects of MI and DU on highly active antiretroviral therapy (HAART) receipt and HIV-RNA suppression among individuals engaged in HIV care. Using 2004 data from the HIV Research Network (HIVRN), we performed a cross-sectional study of HIV-infected patients followed at seven primary care sites. Outcomes of interest were HAART receipt and virological suppression, defined as an HIV-RNA <400 copies/ml. Independent variables of interest were: (1) MI/DU; (2) DU only; (3) MI only; and (4) Neither. We used chi-squared analysis for comparison of categorical variables, and logistic regression to adjust for age, race, sex, frequency of outpatient visits, years in clinical care, CD4 nadir, and study site. During 2004, 10,284 individuals in the HIVRN were either on HAART or HAART eligible defined as a CD4 cell count < or =350. Nearly half had neither MI nor DU (41%), 22% MI only, 15% DU only, and 22% both MI and DU. In multivariate analysis, co-occurring MI/DU was associated with the lowest odds of HAART receipt (Adjusted Odds Ratio: 0.63 (95% CI: (0.55-0.72]), followed by those with DU only (0.75(0.63-0.87)), compared to those with neither. Among those on HAART, concurrent MI/DU (0.66 (0.58-0.75)), DU only (0.77 (0.67-0.88)), were also associated with a decreased odds of HIV-RNA suppression compared to those with neither. MI only was not associated with a statistically significant decrease in HAART receipt (0.93(0.81-1.07)) or viral suppression (0.93 (0.82-1.05)) compared to those with neither. Post-estimation testing revealed a significant difference between those with MI/DU and DU only, and MI/DU and MI only. Co-occurring MI and DU is associated with lower HAART receipt and viral suppression compared to individuals with either MI or DU or neither. Integrating HIV, substance abuse, and mental healthcare may improve outcomes in this population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444675      PMCID: PMC2727701          DOI: 10.1080/09540120802459762

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  30 in total

1.  High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States.

Authors:  Kelly A Gebo; John A Fleishman; Erin D Reilly; Richard D Moore
Journal:  Med Care       Date:  2005-09       Impact factor: 2.983

2.  Improving care for depression in patients with comorbid substance misuse.

Authors:  Katherine E Watkins; Susan M Paddock; Lily Zhang; Kenneth B Wells
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 3.  A review of barriers and facilitators of HIV treatment among injection drug users.

Authors:  Evan Wood; Thomas Kerr; Mark W Tyndall; Julio S G Montaner
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

4.  Substance abuse and the management of medication nonadherence in schizophrenia.

Authors:  Joshua Wilk; Steven C Marcus; Joyce West; Lisa Countis; Rebecca Hall; Darrel A Regier; Mark Olfson
Journal:  J Nerv Ment Dis       Date:  2006-06       Impact factor: 2.254

5.  Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.

Authors:  Brian Wells Pence; William C Miller; Bradley N Gaynes; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

Review 6.  Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder.

Authors:  Mary F Brunette; Kim T Mueser
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

7.  Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness.

Authors:  Peter F Buckley
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

8.  Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women.

Authors:  Judith A Cook; Dennis D Grey; Jane K Burke-Miller; Mardge H Cohen; David Vlahov; Farzana Kapadia; Tracey E Wilson; Robert Cook; Rebecca M Schwartz; Elizabeth T Golub; Kathryn Anastos; Claudia Ponath; Lakshmi Goparaju; Alexandra M Levine
Journal:  Drug Alcohol Depend       Date:  2007-02-08       Impact factor: 4.492

9.  Adherence to antidepressant treatment among privately insured patients diagnosed with depression.

Authors:  Ayse Akincigil; John R Bowblis; Carrie Levin; James T Walkup; Saira Jan; Stephen Crystal
Journal:  Med Care       Date:  2007-04       Impact factor: 2.983

10.  Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use.

Authors:  Seth Himelhoch; Geetanjali Chander; John A Fleishman; James Hellinger; Paul Gaist; Kelly A Gebo
Journal:  Gen Hosp Psychiatry       Date:  2007 Nov-Dec       Impact factor: 3.238

View more
  32 in total

1.  Distress tolerance and use of antiretroviral therapy among HIV-infected individuals in substance abuse treatment.

Authors:  Jessica F Magidson; C J Seitz-Brown; Alyson Listhaus; Briana Lindberg; Katelyn E Anderson; Stacey B Daughters
Journal:  AIDS Patient Care STDS       Date:  2013-09       Impact factor: 5.078

Review 2.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

3.  Residential Eviction and Risk of Detectable Plasma HIV-1 RNA Viral Load Among HIV-Positive People Who Use Drugs.

Authors:  Mary Clare Kennedy; Thomas Kerr; Ryan McNeil; Surita Parashar; Julio Montaner; Evan Wood; M-J Milloy
Journal:  AIDS Behav       Date:  2017-03

Review 4.  Substance use: impact on adherence and HIV medical treatment.

Authors:  Adam Gonzalez; Jennifer Barinas; Conall O'Cleirigh
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

5.  Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes?

Authors:  Anthony T Fojo; Catherine R Lesko; Keri L Calkins; Richard D Moore; Mary E McCaul; Heidi E Hutton; William C Mathews; Heidi Crane; Katerina Christopoulos; Karen Cropsey; Michael J Mugavero; Kenneth Mayer; Brian W Pence; Bryan Lau; Geetanjali Chander
Journal:  AIDS Behav       Date:  2019-03

6.  Social and structural factors associated with greater time with a plasma HIV-1 RNA viral load above log10(1500) copies/ml among illicit drug users.

Authors:  Mary Clare Kennedy; Thomas H Kerr; Evan Wood; Jeannie A Shoveller; Julio S G Montaner; M-J S Milloy
Journal:  AIDS       Date:  2018-05-15       Impact factor: 4.177

7.  Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.

Authors:  M-J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Andrea Krusi; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

8.  Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru.

Authors:  Enrico G Ferro; Damian Weikum; Panagiotis Vagenas; Michael M Copenhaver; Pedro Gonzales; Jesus Peinado; Robinson Cabello; Javier R Lama; Jorge Sanchez; Frederick L Altice
Journal:  AIDS Care       Date:  2014-10-03

Review 9.  Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.

Authors:  Santosh Kumar; Mengyao Jin; Anusha Ande; Namita Sinha; Peter S Silverstein; Anil Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-08-08       Impact factor: 4.481

10.  Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.

Authors:  David B Hanna; Kate Buchacz; Kelly A Gebo; Nancy A Hessol; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; P Todd Korthuis; Richard D Moore; Sonia Napravnik; Pragna Patel; Michael J Silverberg; Timothy R Sterling; James H Willig; Bryan Lau; Keri N Althoff; Heidi M Crane; Ann C Collier; Hasina Samji; Jennifer E Thorne; M John Gill; Marina B Klein; Jeffrey N Martin; Benigno Rodriguez; Sean B Rourke; Stephen J Gange
Journal:  Clin Infect Dis       Date:  2013-01-11       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.